United States· US:31722-008_5d30ffab-38a1-411d-94ad-0a15c227d882
Zafirlukast
A zafirlukast product containing zafirlukast, registered in United States by Camber Pharmaceuticals, Inc.. The same ATC class is registered in 5 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Zafirlukast is registered in 5 of 19 countries.
Countries holding a registration under ATC R03DC01 (zafirlukast), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 4 of them publish a price we can compare per daily dose
Zafirlukast · ATC R03DC01
5 / 19 countries
- Belgiumprice
- Finlandprice
- Norwayprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ZAFIRLUKAST
- Manufacturer
- Camber Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- R03DC01
- ATC class
- Zafirlukast
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 6
- ndc1131722-008-01
- ndc1131722-008-05
- ndc1131722-008-60
- ndc11317220080110 BLISTER PACK in 1 CARTON (31722-008-01) / 10 TABLET, FILM COATED in 1 BLISTER PACK
- ndc113172200805500 TABLET, FILM COATED in 1 BOTTLE (31722-008-05)
- ndc11317220086060 TABLET, FILM COATED in 1 BOTTLE (31722-008-60)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
459 interactions on record for zafirlukast.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Zafirlukast · interactions on record
459 records
- 15 severe
- 265 moderate
- 20 minor
- 159 info
Most severe, free to view
- LonafarnibA16AX20severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Zafirlukast in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9a11b7c9-cfac-4cc8-bf78-71a04b80edf6 GET /v1/drugs/9a11b7c9-cfac-4cc8-bf78-71a04b80edf6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "20",
"substance": "ZAFIRLUKAST",
"productndc": "31722-008",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA212475",
"marketing_category": "ANDA"
}See everything about zafirlukast.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.